Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~At a maximum of 12 weeks after the last cycle of first line standard platinum/taxane intravenous (IV) or intraperitoneal (IP) chemotherapy, patients must fulfill all the following inclusion criteria:~* Age \>/= 18 years;~* Properly executed written informed consent;~* History of histological and CA125 (\> 35 U/ml) confirmed diagnosis of stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer;~* History of debulking surgery and 6-8 cycles of standard platinum/taxane based non-investigational IV-IP chemotherapy;~* Complete clinical response defined as:~* Normal physical examination;~* No symptoms suggestive of persistent cancer;~* No definite evidence of disease by computed tomography (CT) of the abdomen and pelvis within the previous 4 weeks;~* Negative chest x-ray (or chest CT scan) within the previous 4 weeks;~* Serum CA125 within the normal laboratory range.~* Adequate hematologic, renal and hepatic function:~  * Absolute Neutrophil Count (ANC) \>/=1.5 \* 109/l;~ * Platelets \>/= 75 \* 109/l;~ * Haemoglobin \>/= 6.2 mmol/l (\>9.9 g/dl);~ * Serum creatinine \</= 1.5 \* ULN (Upper Limit of Normal);~ * Bilirubin \</= 1.5 \* ULN; AST, ALT, AP \</= 2.5 \* ULN.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \</= 2.~Exclusion Criteria:~Patients are ineligible to participate in the study, if any of the following criteria are present:~* any other invasive malignancies, with the exception of non-melanoma skin cancer or cervical carcinoma in situ, within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy;~* known active autoimmune disease requiring chronic treatment with immunosuppressive agents (e.g., rheumatoid arthritis, ulcerative colitis, etc.);~* known immune deficiency (e.g. HIV, hypogammaglobulinemia, etc.);~* known infection with hepatitis B, or hepatitis C;~* history of recent myocardial infarction (\</= 6 months) or decompensated heart failure (New York Heart Association - NYHA class \>/= III);~* previous or concomitant use of any anti-cancer therapy other than the platinum-taxane based 1st line chemotherapy for ovarian cancer; any maintenance or consolidation therapy is not permitted after completion of standard front line chemotherapy.~* concomitant use of any other investigational agent;~* any prior investigational anti-cancer vaccine or monoclonal antibody;~* known allergy to murine proteins;~* any significant medical or psychiatric condition, drug or alcohol abuse that might prevent the patient from complying with all study procedures;~* clinically significant active infection;~* concomitant use of any immunosuppressive agent (e.g., steroids, cyclosporin, etc.);~* major surgery within the previous 2 weeks;~* radiotherapy within the previous 4 weeks;~* any significant toxicity from prior chemotherapy;~* unreliability or inability to follow protocol requirements;~* potentially childbearing and not willing to use adequate contraceptive methods throughout the entire study period;~* pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abagovomab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy